A comparison of self- and observer-rated scales for detecting clinical improvement during repetitive transcranial stimulation (rTMS) treatment of depression

Psychiatry Res. 2023 Dec:330:115608. doi: 10.1016/j.psychres.2023.115608. Epub 2023 Nov 14.

Abstract

Clinical outcomes of repetitive Transcranial Magnetic Stimulation (rTMS) for treatment of Major Depressive Disorder (MDD) vary widely, and no single mood rating scale is standard for assessing rTMS outcomes. This study of 708 subjects undergoing clinical rTMS compared the performance of four scales in measuring symptom change during rTMS treatment. Self-report and observer ratings were examined weekly with the Inventory of Depressive Symptomatology 30-item (IDS), Patient Health Questionnaire 9-item (PHQ), Profile of Mood States 30-item (POMS), and Hamilton Depression Rating Scale 17-item (HDRS). While all scales were correlated and detected significant improvement, the degree of improvement over time as well as response (33-50%) and remission (20-24%) rates varied significantly. Higher baseline severity was associated with lower likelihood of remission, and greater improvement by sessions 5 and 10 predicted response across all scales. Use of only a single scale to assess outcome conferred 14-36% risk of failing to detect response/remission indicated by another scale. The PHQ was most likely to indicate improvement and least likely to miss response or remission. These findings indicate that assessment of symptom burden during rTMS treatment may be most accurately assessed through use of multiple instruments.

Keywords: Early improvement; Major Depressive Disorder (MDD); Measurement-based care; Mood rating scales; Repetitive transcranial magnetic stimulation (rTMS).

MeSH terms

  • Depression
  • Depressive Disorder, Major* / diagnosis
  • Depressive Disorder, Major* / therapy
  • Humans
  • Prefrontal Cortex / physiology
  • Transcranial Magnetic Stimulation
  • Treatment Outcome